JamesMCroopMD

Pediatric Hematology & Oncology • Indianapolis, IN

Pediatric Hematologic Oncology

Professor of Pediatrics, Indiana University

Join to view full profile

Dr. Croop is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Croop's full profile

Already have an account?

Office
705 Riley Hospital Dr
Roc 4340
Indianapolis, IN 46202
Phone+1 317-944-2143

Fax+1 317-944-3107
Is this information wrong?

Education & Training

Children's Hospital/Boston Medical CenterFellowship, Pediatric Hematology/Oncology, 1983 - 1986
Children's Hospital of PhiladelphiaResidency, Pediatrics, 1980 - 1983
Perelman School of Medicine at the University of PennsylvaniaClass of 1980

Certifications & Licensure

IN State Medical License 1997 - 2025
MA State Medical License 1983 - 2011
PA State Medical License 1982 - 1988
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2009-2014
America's Top Doctors for Cancer Castle Connolly, 2008-2013
Indianapolis Monthly Castle Connolly, 2011, 2013
Whos Who in Medicine and Healthcare Marquis Whos Who
Join now to see all

Clinical Trials

Combination Chemotherapy Plus Gene Therapy in Treating Patients With CNS Tumors Start of enrollment: 2000 Feb 01
Completed
Phase 1
Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma Start of enrollment: 2001 Oct 18
Active, not recruiting
Phase 3
Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor Start of enrollment: 2007 Feb 26
Active, not recruiting
Phase 3
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia Start of enrollment: 2007 Mar 01
Completed
Phase 3
Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET Start of enrollment: 2007 Mar 26
Active, not recruiting
Phase 3
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma Start of enrollment: 2007 Jan 22
Active, not recruiting
Phase 3
Talotrexin in Treating Young Patients With Recurrent Solid Tumors or Leukemia That is Recurrent or Does Not Respond to Treatment Start of enrollment: 2007 Feb 01
Withdrawn
Phase 1
Assessing Ear Damage in Young Cancer Patients Treated With Cisplatin Start of enrollment: 2007 May 01
Completed
Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Start of enrollment: 2008 Jan 15
Active, not recruiting
Phase 3
Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System Start of enrollment: 2008 Dec 08
Active, not recruiting
Phase 3
Genetic Mutations and Environmental Exposure in Young Patients With Retinoblastoma and in Their Parents and Young Healthy Unrelated Volunteers Start of enrollment: 2008 Jun 02
Completed
Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy Start of enrollment: 2008 Jun 23
Completed
Phase 3
Neuropsychological and Behavioral Testing in Younger Patients With Cancer Start of enrollment: 2009 Feb 27
Recruiting
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia Start of enrollment: 2009 Mar 09
Completed
Phase 3
Collecting and Storing Samples of Bone Marrow and Blood From Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma Start of enrollment: 2006 Sep 25
Completed
Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer Start of enrollment: 2003 Oct 13
Completed
Study of Kidney Tumors in Younger Patients Start of enrollment: 2006 Feb 27
Recruiting
Collecting and Storing Samples of Blood and Tumor Tissue From Patients With Osteosarcoma Start of enrollment: 2008 Feb 04
Completed
Collecting and Storing Biological Samples From Patients With Ewing Sarcoma Start of enrollment: 2008 Feb 04
Completed
Collecting and Storing Biological Samples From Young Patients With Hodgkin?s Lymphoma Start of enrollment: 2006 Oct 23
Completed
Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma Start of enrollment: 2000 Nov 06
Recruiting
Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma Start of enrollment: 1999 Mar 15
Completed
Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma Start of enrollment: 2009 Sep 21
Completed
Phase 1, Phase 2
Study of Blood Samples From Newborns With Down Syndrome Start of enrollment: 2009 Feb 23
Completed
Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer Start of enrollment: 2009 Sep 14
Active, not recruiting
Phase 3
Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma Start of enrollment: 2005 May 30
Completed
Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma Start of enrollment: 2010 Jan 01
Completed
Phase 2
A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL) Start of enrollment: 2011 Apr 14
Completed
Phase 1
Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma Start of enrollment: 2010 May 07
Active, not recruiting
Phase 3
Risk-Based Classification System of Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Start of enrollment: 2010 Aug 09
Completed
Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia Start of enrollment: 2011 Feb 01
Completed
Phase 2
INCB18424 in Treating Young Patients With Relapsed or Refractory Solid Tumor, Leukemia, or Myeloproliferative Disease Start of enrollment: 2010 Sep 01
Completed
Phase 1
Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma Start of enrollment: 2010 Aug 09
Active, not recruiting
Phase 3
Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors Start of enrollment: 2010 Nov 22
Completed
Phase 2
Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma Start of enrollment: 2010 Oct 01
Completed
Phase 2
Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma Start of enrollment: 2010 Nov 22
Active, not recruiting
Phase 3
MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia Start of enrollment: 2011 Jan 01
Completed
Phase 1
Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma Start of enrollment: 2011 May 01
Completed
Phase 1
Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant Start of enrollment: 2011 Mar 01
Completed
Phase 3
Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia Start of enrollment: 2011 Apr 04
Completed
Phase 3
Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma Start of enrollment: 2011 Sep 01
Completed
Phase 2
Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation Start of enrollment: 2011 Sep 01
Completed
Phase 3
Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Jun 20
Active, not recruiting
Phase 3
Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma Start of enrollment: 2011 Sep 01
Completed
Phase 1
A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC# 606869) in the Very High Risk Stratum Start of enrollment: 2012 Feb 01
Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma Start of enrollment: 2012 Jan 01
Completed
Phase 2
Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors Start of enrollment: 2012 Nov 14
Completed
Phase 1
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma Start of enrollment: 2013 Nov 01
Completed
Phase 1
Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma Start of enrollment: 2013 Jan 31
Completed
Phase 1, Phase 2
Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas Start of enrollment: 2013 Sep 03
Completed
Phase 1
ICON1: Treatment Decisions and Outcomes in Pediatric Refractory ITP Start of enrollment: 2013 Aug 01
Completed
Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors Start of enrollment: 2014 Mar 28
Completed
Phase 1, Phase 2
Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies Start of enrollment: 2014 May 16
Completed
Phase 1, Phase 2
VEGF Receptor Tyrosine Kinase Inhibitor Axitinib in Children With Recurrent or Refractory Solid Tumors Start of enrollment: 2014 Sep 01
Completed
Phase 1
A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors Start of enrollment: 2015 Dec 11
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

A phase 1 trial utilizing a pharmacokinetic endpoint to determine the optimal dose of ramucirumab in children and adolescents with relapsed or refractory solid tumors,...
Kristy L Pilbeam, Kamnesh Pradhan, James Croop, Charles G Minard, Xiaowei Liu, Stephan D Voss, Emasenyie Isikwei, Stacey L Berg, Joel M Reid, Elizabeth Fox, Brenda J W...> ;Pediatric Blood & Cancer. 2024 Mar 1
2 citations
PRL2 phosphatase enhances oncogenic FLT3 signaling via dephosphorylation of the E3 ubiquitin ligase CBL at tyrosine 371.
Hongxia Chen, Yunpeng Bai, Michihiro Kobayashi, Shiyu Xiao, Wenjie Cai, Sergio Barajas, Sisi Chen, Jinmin Miao, Frederick Nguele Meke, Sasidhar Vemula, James P Ropa, J...> ;Blood. 2023 Jan 19
A phase 1, first-in-child, multicenter study to evaluate the safety and efficacy of the oncolytic herpes virus talimogene laherparepvec in pediatric patients with adva...
Lucas Moreno, Pierre Teira, James M Croop, Nicolas U Gerber, Nicolas André, Isabelle Aerts, Luis Gros Subias, Bram De Wilde, Francisco Bautista, Brian Turpin, Srinivas...> ;Frontiers in Pediatrics. 2023 Jan 1
2 citations
Parents' Insights into Pediatric Oncology Phase I Clinical Trials: Experiences from Their Child's Participation.
Stacey Crane, James M. Croop, Jill Lee, Jamie Walski, Joan E. Haase> ;Seminars in Oncology Nursing. 2021 Jun 1
7 citations
Evidence for BCR/ABL1-positive T-cell acute lymphoblastic leukemia arising in an early lymphoid progenitor cell.
Susanne Ragg, Barbara K. Zehentner, Michael R. Loken, James M. Croop> ;Pediatric Blood & Cancer. 2019 Sep 1
7 citations
Phosphatase PRL2 promotes oncogenic NOTCH1-Induced T-cell leukemia
Michihiro Kobayashi, Yunpeng Bai, Sisi Chen, Rui Gao, Chonghua Yao, Wenjie Cai, Angelo A. Cardoso, James Croop, Zhong Yin Zhang, Yan Liu> ;Leukemia. 2017 Mar 1
16 citations
Fever and neutropenia hospital discharges in children with cancer: A 2012 update.
Emily L. Mueller, James M. Croop, Aaron E. Carroll> ;Pediatric Hematology and Oncology. 2016 Feb 22
144 citations
Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial
Kent A. Robertson, Grzegorz Nalepa, Feng Chun Yang, Daniel C. Bowers, Chang Y. Ho, Gary D. Hutchins, James M. Croop, Terry A. Vik, Scott C. Denne, Luis F. Parada, Cynt...> ;The Lancet. Oncology. 2012 Dec 1
24 citations
Clinical course of postthrombotic syndrome in children with history of venous thromboembolism.
Susan Creary, Mark E. Heiny, James M. Croop, Robert Fallon, Terry A. Vik, Monica L. Hulbert, Holly M. Knoderer, Manjusha Kumar, Anjali Sharathkumar> ;Blood Coagulation & Fibrinolysis. 2012 Jan 1
12 citations
Population pharmacokinetics of intravenous ondansetron in oncology and surgical patients aged 1−48 months
John T. Mondick, Brendan M. Johnson, Lynda J. Haberer, Mark E. Sale, Peter C. Adamson, Charles J. Coté, James M. Croop, Mark W. Russo, Jeffrey S. Barrett, J. Frank Hoke> ;European Journal of Clinical Pharmacology. 2010 Jan 1
19 citations
A pilot study of dose-intensified procarbazine, CCNU, vincristine for poor prognosis brain tumors utilizing fibronectin-assisted, retroviral-mediated modification of C...
K Cornetta, James M. Croop, Edward J. Dropcho, Rafat Abonour, Mark W. Kieran, Susan G. Kreissman, Lilith Reeves, Leonard C. Erickson, David A. Williams> ;Cancer Gene Therapy. 2006 Apr 28
92 citations
Phase I and Pharmacokinetic Study of Gefitinib in Children With Refractory Solid Tumors: A Children’s Oncology Group Study
Najat C. Daw, Wayne L. Furman, Clinton F. Stewart, Lisa C. Iacono, Mark Krailo, Mark L. Bernstein, Janet Dancey, Rose Anne Speights, Susan M. Blaney, James M. Croop, G...> ;Journal of Clinical Oncology. 2005 Sep 1
9 citations
Germline p53 mutation presenting as synchronous tumors.
Mary Ellen Cavalier, Mary Davis, James M. Croop> ;Journal of Pediatric Hematology/oncology. 2005 Aug 1
18 citations
Treatment, outcome, and cost of care in children with idiopathic thrombocytopenic purpura
Manjusha Kumar, Terry A. Vik, Cynthia S. Johnson, M. Elaine Southwood, James M. Croop> ;American Journal of Hematology. 2005 Mar 1
7 citations
Gene therapy for fanconi anemia.
James M. Croop> ;Current Hematology Reports. 2003 Jul 1
46 citations
Mobilization and collection of peripheral blood CD34+ cells from patients with Fanconi anemia
James M. Croop, Ryan J. Cooper, C. Fernández, Vicki Graves, Susan G. Kreissman, Helmut Hanenberg, Franklin O. Smith, David R. Williams> ;Blood. 2001 Nov 15
35 citations
Packaging Cell Line DNA Contamination of Vector Supernatants: Implication for Laboratory and Clinical Research
Jun Chen, Lilith Reeves, Nathan Sanburn, James M. Croop, David R. Williams, Kenneth Cornetta> ;Virology. 2001 Mar 30
14 citations
Large-scale mobilization and isolation of CD34+ cells from normal donors.
James M. Croop, Ryan J. Cooper, Roopa Seshadri, C Fernandez, V Graves, Susan G. Kreissman, F O Smith, K Cornetta, David A. Williams, Rafat Abonour> ;Bone Marrow Transplantation. 2000 Dec 1
38 citations
Multidrug resistance gene expression correlates with progesterone production in dehydroepiandrosterone-induced polycystic and equine chorionic gonadotropin-stimulated ...
Gloria Y. Lee, James M. Croop, Everett Anderson> ;Biology of Reproduction. 1998 Feb 1
33 citations
Characterization of P-glycoprotein transport and inhibition in vivo.
Eva Barbarics, James F. Kronauge, Dalia Cohen, Alan Davison, Alun G. Jones, James M. Croop> ;Cancer Research. 1998 Jan 15
45 citations
EVOLUTIONARY RELATIONSHIPS AMONG ABC TRANSPORTERS
James M. Croop> ;Methods in Enzymology. 1998 Jan 1
104 citations
Gene immunotherapy in murine acute myeloid leukemia: granulocyte-macrophage colony-stimulating factor tumor cell vaccines elicit more potent antitumor immunity compare...
Kyriaki Dunussi-Joannopoulos, Glenn Dranoff, Howard J. Weinstein, James L.M. Ferrara, Barbara E. Bierer, James M. Croop> ;Blood. 1998 Jan 1
25 citations
Gene therapy with B7.1 and GM-CSF vaccines in a murine AML model.
Kyriaki Dunussi-Joannopoulos, Howard J. Weinstein, Robert J. Arceci, James M. Croop> ;Journal of Pediatric Hematology/oncology. 1997 Nov 1
114 citations
Phosphatidylcholine and Phosphatidylethanolamine Behave as Substrates of the Human MDR1 P-Glycoprotein†
Irene Bosch, Kyriaki Dunussi-Joannopoulos, Rui Lian Wu, Stephen T. Furlong, James M. Croop> ;Biochemistry. 1997 May 13
23 citations
CD8+ T cells activated during the course of murine acute myelogenous leukemia elicit therapeutic responses to late B7 vaccines after cytoreductive treatment
Kyriaki Dunussi-Joannopoulos, Werner Krenger, Howard J. Weinstein, James L.M. Ferrara, James M. Croop> ;Blood. 1997 Apr 15
Join now to see all

Press Mentions

Riley Doctor Using Magic as MedicineFebruary 7th, 2019

Grant Support

Transduction Of Cd34+Periph.Bld Cells W/Gp91 In X-Linked Chr Granulomatous DIS.National Center For Research Resources2004
Procarbazine, CCNU, Vincristine For Poor Prognosis Pediatric/Adult Brain TumorNational Center For Research Resources2004
Clinical Research FacilityNational Cancer Institute2000–2002
Core--Gene Therapy Working Group/BiostatisticsNational Institute Of Diabetes And Digestive And Kidney Diseases1999–2002
Immunologic Analysis--Multidrug Resistant Gene FamilyNational Cancer Institute1988–1992
Multidrug Resistance Genes--Analysis And ApplicationsNational Cancer Institute1987–1991